Inception on
For the For the July 1, 1998
Six Months Ended Six Months Ended through
December 31, December 31, December 31, 2007
2007 2006
Revenue $377,500 $262,500 $1,095,833
Operating Expenses:
General and
administrative 974,910 1,486,879 20,409,103
Research and
development 745,149 548,743 8,938,318
Total Operating
Expenses 1,720,059 2,035,622 29,347,421
Loss From
Operations (1,342,559) (1,773,122) (28,251,588)
Sale of state
income tax loss, net -- -- 586,442
Other noncash income -- -- 321,259
Interest income, net 32,106 37,020 411,894
Amortization of debt
discount and
financing costs (298,428) -- (298,428)
Interest expense
on convertible notes (67,836) -- (67,836)
Net Loss $(1,676,717) $(1,736,102) $(27,298,257)
Basic and Diluted
Net Loss Per
Common Share $(0.10) $(0.11)
Basic and Diluted
Weighted Average
Number of Common
Shares Outstanding 17,474,282 16,369,220
SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONDENSED CONSOLIDATED BALANCE SHEETS
December 31, June 30,
2007 2007
<
'/>"/>SOURCE Senesco Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing2.
Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies3.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering4.
Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction5.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results6.
BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery7.
Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators8.
China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day9.
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth10.
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership11.
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel